Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072653 | 1.00 | SIGMAR1 (0.46) | SIGMAR1GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL4072649 | 1.00 | SIGMAR1 (0.46) | SIGMAR1GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL26690669 | 0.85 | ALOX5 (0.47) | SIGMAR1FUCA1S1PR1S1PR5ALDH1A1 | |
| SCHEMBL26690672 | 0.85 | ALOX5 (0.47) | SIGMAR1FUCA1S1PR1S1PR5ALDH1A1 | |
| SCHEMBL3318028 | 0.79 | ACHE (0.46) | SIGMAR1FUCA1S1PR1S1PR5 | |
| SCHEMBL3318031 | 0.79 | ACHE (0.46) | SIGMAR1FUCA1S1PR1S1PR5 | |
| SCHEMBL7495381 | 0.78 | SMN1; SMN2 (0.38) | SIGMAR1FUCA1ALDH1A1MEN1KMT2A | |
| SCHEMBL7495387 | 0.78 | SMN1; SMN2 (0.38) | SIGMAR1FUCA1ALDH1A1MEN1KMT2A | |
| SCHEMBL24326686 | 0.77 | FUCA1 (0.53) | SIGMAR1GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL4068578 | 0.76 | TOP2A (0.36) | SIGMAR1FUCA1ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3559007-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119444-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | SIGMAR1 900/4885GBA1 142/4885FUCA1 87/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | SIGMAR1 965/4885GBA1 505/4885FUCA1 23/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | SIGMAR1 900/4885GBA1 142/4885FUCA1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.